Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2018’, provides an overview of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Adrenocortical Carcinoma (Adrenal Cortex Cancer)

- The report reviews pipeline therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Adrenocortical Carcinoma (Adrenal Cortex Cancer) therapeutics and enlists all their major and minor projects

- The report assesses Adrenocortical Carcinoma (Adrenal Cortex Cancer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ArQule Inc

Bristol-Myers Squibb Co

Exelixis Inc

Infinity Pharmaceuticals Inc

Merck KGaA

Millendo Therapeutics Inc

Orphagen Pharmaceuticals Inc

ArQule Inc

Bristol-Myers Squibb Co

Exelixis Inc

Infinity Pharmaceuticals Inc

Merck KGaA

Millendo Therapeutics Inc

Orphagen Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 4

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Overview 5

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Development 6

Adrenocortical ...

Table of Contents

Table of Contents 2

Introduction 4

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Overview 5

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Development 6

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Assessment 12

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Companies Involved in Therapeutics Development 20

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Drug Profiles 24

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects 103

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products 104

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Product Development Milestones 105

Appendix 114

List of Tables

List of Tables

Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H2 2018

Number of Products under Development by Companies, H2 2018 ...

List of Tables

Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by ArQule Inc, H2 2018

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Bristol-Myers Squibb Co, H2 2018

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Exelixis Inc, H2 2018

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Infinity Pharmaceuticals Inc, H2 2018

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Merck KGaA, H2 2018

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Millendo Therapeutics Inc, H2 2018

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Orphagen Pharmaceuticals Inc, H2 2018

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects, H2 2018

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H2 2018

Number of Products under Development by Companies, H2 2018 ...

List of Figures

Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports